Following this year’s South by Southwest (SXSW) conference in Austin, Texas, it occurred to me that the progression of SXSW matches what I’ve seen – and
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh